(AGA) on the management of mild-to-moderate ulcerative colitis (UC). The guideline was
developed by the AGA Institute's Clinical Guidelines Committee and approved by the AGA …

S3 Evidence-Based Systematic Review on Medical Therapies for IBD also has a high
incidence in New Zealand, suggesting that the disease may get more common the further …

11.1. General The treatment strategy for ulcerative colitis [UC] is mainly based on the
severity, distribution [proctitis, left-sided, extensive] 1 and pattern of disease. The latter …

When deciding the appropriate treatment strategy for active ulcerative colitis one should
consider the activity, distribution (proctitis, left-sided, extensive 1), and pattern of disease …

Objectives: Endoscopic remission in ulcerative colitis (UC) is associated with improved
clinical outcomes. We assessed whether histological remission predicts clinical outcomes …

OBJECTIVES: The efficacy of 5-aminosalicylic acids (5-ASAs) in ulcerative colitis (UC) has
been studied previously in meta-analyses. However, several randomized controlled trials …

Background and Aims Assessment of disease activity is essential for developing and
determining appropriate therapy in patients with ulcerative colitis (UC). Validated clinical …

Conventional therapies for ulcerative colitis and Crohn's disease (CD) include
aminosalicylates, corticosteroids, thiopurines, methotrexate, and anti–tumor necrosis factor …

Background Mesalazine is the most commonly prescribed medication for mild to moderate
ulcerative colitis. It is generally well tolerated with some reported side effects. Aim To …

Background Oral 5‐aminosalicylic (5‐ASA) preparations were intended to avoid the adverse
effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was …